Home / Companies / News / Cipla working on multiple therapies to fight spread of coronavirus

Cipla working on multiple therapies to fight spread of coronavirus

Besides, the company is reworking its domestic market sales strategy, and scrutinising its capital and operating expenditure plans

Premium

Cipla is among the three Indian companies that signed a non-exclusive licensing agreement with US-based Gilead Sciences last week to make and distribute the latter’s repurposed Ebola drug Remdesivir in 127 countries including India

Sohini Das Mumbai

4 min read Last Updated : May 17 2020 | 10:23 PM IST

Mumbai-based drug maker Cipla is working on different therapies for the novel coronavirus, including its newly licensed Remdesivir, the anti-HIV drug combination (Lopinavir and Ritonavir) as well as the biologic drug Tociluzumab from Roche, which it exclusively sells in India.

Besides, the company is reworking its domestic market sales strategy, and scrutinising its capital and operating expenditure plans. Cipla is among the three Indian companies that signed a non-exclusive licensing agreement with US-based Gilead Sciences last week to make and distribute the latter’s repurposed Ebola drug Remdesivir in 127 countries including India. Cipla has started working on the project, and the

Topics : Coronavirus Cipla

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in